Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions

被引：0
|
作者：
Luszczki, Jarogniew J. [1 ,2 ]
机构：
[1] Med Univ Lublin, Dept Pathophysiol, PL-20090 Lublin, Poland
[2] Inst Agr Med, Dept Physiopathol, PL-20950 Lublin, Poland
来源：
PHARMACOLOGICAL REPORTS | 2009年 / 61卷 / 02期
关键词：
antiepileptic drugs; brivaracetam; carabersat; carisbamate; DP-valproic acid; drug interactions; eslicarbazepine; fluorofelbamate; fosphenytoin; ganaxolone; lacosamide; losigamone; pharmacokinetics; pregabalin; remacemide; retigabine; rufinamide; safinamide; seletracetam; soretolide; stiripentol; talampanel; valrocemide; ESLICARBAZEPINE-ACETATE BIA-2-093; ADVERSE EVENT PROFILE; REMACEMIDE HYDROCHLORIDE; DOUBLE-BLIND; ADD-ON; ANTICONVULSANT DRUG; PROGRESS REPORT; IN-VITRO; CARISBAMATE RWJ-333369; GABA(A) RECEPTOR;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
This review briefly summarizes the information on the molecular mechanisms of action, pharmacokinetic profiles and drug interactions of novel (third-generation) antiepileptic drugs, including brivaracetam, carabersat, carisbamate, DP-valproic acid, eslicarbazepine, fluorofelbamate, fosphenytoin, ganaxolone, lacosamide, losigamone, pregabalin, remacemide, retigabine, rufinamide, safinamide, seletracetam, soretolide, stiripentol, talampanel, and valrocemide. These novel antiepileptic drugs undergo intensive clinical investigations to assess their efficacy and usefulness in the treatment of patients with refractory epilepsy.
引用
收藏
页码：197 / 216
页数：20
相关论文
共 50 条
  • [1] Third-generation antiepileptic drugs: Mechanisms of action, pharmacokinetics and interactions
    Łuszczki J.J.
    Pharmacological Reports, 2009, 61 (2) : 197 - 216
  • [2] Pharmacodynamics and common drug-drug interactions of the third-generation antiepileptic drugs
    Stefanovic, Srdan
    Jankovic, Slobodan M.
    Novakovic, Milan
    Milosavljevic, Marko
    Folic, Marko
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2018, 14 (02) : 153 - 159
  • [3] Drug interactions involving the new second- and third-generation antiepileptic drugs
    Landmark, Cecilie Johannessen
    Patsalos, Philip N.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2010, 10 (01) : 119 - 140
  • [4] PHARMACOKINETICS AND INTERACTIONS OF ANTIEPILEPTIC DRUGS
    GRAVES, NM
    AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1993, 50 (12): : S23 - S29
  • [5] Teratogenic potential of third-generation antiepileptic drugs: Current status and research needs
    K. P. Singh
    Niharika Verma
    Pharmacological Reports, 2019, 71 : 491 - 502
  • [6] Teratogenic potential of third-generation antiepileptic drugs: Current status and research needs
    Singh, K. P.
    Verma, Niharika
    PHARMACOLOGICAL REPORTS, 2019, 71 (03) : 491 - 502
  • [7] Third-generation thrombolytic drugs
    Verstraete, M
    AMERICAN JOURNAL OF MEDICINE, 2000, 109 (01): : 52 - 58
  • [8] Pharmacokinetics of third-generation aromatase inhibitors
    Lonning, P
    Pfister, C
    Martoni, A
    Zamagni, C
    SEMINARS IN ONCOLOGY, 2003, 30 (04) : 23 - 32
  • [9] Mechanisms of action of antiepileptic drugs
    White, H. Steve
    Smith, Misty D.
    Wilcox, Karen S.
    NEUROBIOLOGY OF EPILEPSY AND AGING, 2007, 81 : 85 - 110
  • [10] MECHANISMS OF ACTION OF ANTIEPILEPTIC DRUGS
    MORSELLI, PL
    REVUE NEUROLOGIQUE, 1987, 143 (05) : 406 - 412
12345